文献速递技术与安全胸部腹部CTMRPET

Delta影像组学:系统综述

Delta radiomics: a systematic review.
PubMed 文献 · Radiol Med · 2021-12-04

该系统综述纳入48项研究,评估Delta影像组学(分析不同采集时间点,通常为治疗前后,的影像组学特征变化)在肿瘤学中的应用。研究覆盖直肠癌、肺癌、肉瘤、前列腺癌、头颈癌及胃肠道恶性肿瘤等,中位RQS为25%,多数研究质量较低。结论认为Delta影像组学在肿瘤学多个临床终点显示潜在获益,但当前证据异质性大、不稳健且不可重复,需前瞻性多中心研究进行临床验证。

要点

  • Delta影像组学分析治疗前后等不同时间点的影像组学特征变化,而非单时间点静态特征。
  • 纳入48项研究中,肺癌12项(25%)最多,其次为胃肠道恶性肿瘤(除直肠)7项(14.6%)、直肠癌和头颈癌各6项(12.5%)。
  • 全部研究中位RQS仅25%(均值21%±12%),13项(30.2%)质量评分<10%,22项(51.2%)<25%。

核心结论

  • Delta影像组学在肿瘤学的鉴别诊断、预后与治疗反应预测及副作用评估等多个临床终点显示出潜在获益。
  • 但纳入研究整体质量偏低存在偏倚,结论目前异质性大、不稳健且不可重复。
  • 需要前瞻性多中心研究对Delta影像组学方法进行临床验证。

研究设计与样本

  • 系统综述,检索Embase、PubMed和ScienceDirect,检索词包含radiomics、texture和delta三个关键检索词的自由文本和/或MeSH词。
  • 最终纳入48项研究,使用QUADAS-2和RQS工具进行分析。
  • 研究按部位分为:临床前/方法学5项(10.4%)、直肠癌6项(12.5%)、肺癌12项(25%)、肉瘤5项(10.4%)、前列腺癌3项(6.3%)、头颈癌6项(12.5%)、除直肠外的胃肠道恶性肿瘤7项(14.6%)、其他疾病部位4项(8.3%)。

诊断标准与关键数值

  • 采用QUADAS-2进行偏倚风险评价,采用RQS工具进行影像组学研究质量评分。
  • 全部研究中位RQS为25%(均值21%±12%),13项研究(30.2%)质量评分<10%,22项研究(51.2%)<25%。

临床应用与阅片要点

  • Delta影像组学可基于治疗前后不同时间点的影像组学特征变化进行分析,用于肿瘤鉴别诊断、预后与治疗反应预测及副作用评估。
  • 由于纳入研究方法学质量普遍偏低且结论异质性大,原文未据此给出可直接用于日常阅片或报告的推荐。

局限性

  • 纳入研究总体质量偏低存在偏倚。
  • 当前结论异质性大、不稳健且不可重复。
  • 需要前瞻性多中心研究进行临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Radiomics can provide quantitative features from medical imaging that can be correlated with various biological features and clinical endpoints. Delta radiomics, on the other hand, consists in the analysis of feature variation at different acquisition time points, usually before and after therapy. The aim of this study was to provide a systematic review of the different delta radiomics approaches.

METHODS: Eligible articles were searched in Embase, PubMed, and ScienceDirect using a search string that included free text and/or Medical Subject Headings (MeSH) with three key search terms: "radiomics", "texture", and "delta". Studies were analysed using QUADAS-2 and the RQS tool.

RESULTS: Forty-eight studies were finally included. The studies were divided into preclinical/methodological (five studies, 10.4%); rectal cancer (six studies, 12.5%); lung cancer (twelve studies, 25%); sarcoma (five studies, 10.4%); prostate cancer (three studies, 6.3%), head and neck cancer (six studies, 12.5%); gastrointestinal malignancies excluding rectum (seven studies, 14.6%), and other disease sites (four studies, 8.3%). The median RQS of all studies was 25% (mean 21% ± 12%), with 13 studies (30.2%) achieving a quality score < 10% and 22 studies (51.2%) < 25%.

CONCLUSIONS: Delta radiomics shows potential benefit for several clinical endpoints in oncology (differential diagnosis, prognosis and prediction of treatment response, and evaluation of side effects). Nevertheless, the studies included in this systematic review suffer from the bias of overall low quality, so that the conclusions are currently heterogeneous, not robust, and not replicable. Further research with prospective and multicentre studies is needed for the clinical validation of delta radiomics approaches.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Nardone, Reginelli, Grassi, et al. Delta radiomics: a systematic review. Radiol Med. 2021. PMID: 34865190. doi:10.1007/s11547-021-01436-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。